Bryostatin 1 analogues - Aphios

Drug Profile

Bryostatin 1 analogues - Aphios

Alternative Names: APH-0703; APH-1104; Bryosomes; Bryostatin 1-containing phospholipid nanosomes (Bryosomes™) - Aphios; Nanoencapsulated APH 0703

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; Louisiana State University; University Hospital Muenster
  • Class Antineoplastics; Macrocyclic compounds
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Reperfusion injury
  • Discontinued Oesophageal cancer

Most Recent Events

  • 03 May 2017 Preclinical trials in Reperfusion injury in USA, Germany (unspecified route)
  • 03 May 2017 Preclinical data in Reperfusion injury presented at the 2017 American Transplant Congress (ATC-2017)
  • 20 Oct 2014 Aphios is investigating oral bryostatin 1 analogue, APH 1104, for the treatment of Alzheimer's disease and Cognition disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top